Sugi Predict

Sugi Predict / Compounds / SCHEMBL349175

SCHEMBL349175

SCHEMBL349175

CCOC(=O)c1sc(NC(=O)OC(C)(C)C)nc1C

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.68
▸ HPGD P15428 5/20 0.68
▸ TSHR P16473 2/20 0.67
▸ NPC1 O15118 5/20 0.62
▸ KDM4E B2RXH2 2/20 0.58
▸ LMNA P02545 2/20 0.58
▸ NPSR1 Q6W5P4 2/20 0.58
▸ LCK P06239 4/20 0.58
▸ SMN1; SMN2 Q16637 6/20 0.57
▸ HTT P42858 2/20 0.57
▸ GAA P10253 2/20 0.56
▸ RXFP1 Q9HBX9 1/20 0.56
▸ RAB9A P51151 4/20 0.55
▸ MEN1 O00255 2/20 0.55
▸ KMT2A Q03164 2/20 0.55
▸ TP53 P04637 1/20 0.55
▸ HSP90AA1 P07900 1/20 0.55
▸ NFKB1 P19838 1/20 0.55
▸ NFKB2 Q00653 1/20 0.55
▸ RELA Q04206 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL539568 0.87 LCK (0.62) ALDH1A1HPGDTSHRNPC1KDM4E
SCHEMBL370875 0.87 ALDH1A1 (0.51) ALDH1A1HPGDTSHRNPC1KDM4E
SCHEMBL8555317 0.86 ALDH1A1 (0.76) ALDH1A1HPGDTSHRNPC1KDM4E
SCHEMBL25254005 0.86 KIFC1 (0.64) ALDH1A1HPGDTSHRNPC1KDM4E
SCHEMBL12273225 0.85 TSHR (0.49) ALDH1A1HPGDTSHRNPC1KDM4E
SCHEMBL31214308 0.85 TSHR (0.49) ALDH1A1HPGDTSHRNPC1KDM4E
SCHEMBL25297039 0.84 ALDH1A1 (0.55) ALDH1A1HPGDTSHRNPC1KDM4E
SCHEMBL2718161 0.84 TSHR (0.51) ALDH1A1HPGDTSHRNPC1KDM4E
SCHEMBL24735699 0.83 LCK (0.63) ALDH1A1TSHRNPC1KDM4ELMNA
SCHEMBL538349 0.83 LCK (0.63) ALDH1A1HPGDTSHRNPC1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12545654-B2 MYC inhibitors and uses thereof STEMSYNERGY THERAPEUTICS, INC. (US) 2026-02-10 — — US disclosed
US-11993595-B2 Compounds MISSION THERAPEUTICS LIMITED (GB) 2024-05-28 — — US disclosed
CN-111592534-B New compounds 特殊治疗有限公司 2023-06-30 — — CN disclosed
US-20230150956-A1 MYC INHIBITORS AND USES THEREOF STEMSYNERGY THERAPEUTICS, INC. 2023-05-18 — — US disclosed
US-20230150956-A1 MYC INHIBITORS AND USES THEREOF STEMSYNERGY THERAPEUTICS, INC. 2023-05-18 — — US disclosed
US-20230052191-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2023-02-16 — — US disclosed
US-20230052191-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2023-02-16 — — US disclosed
EP-4103188-A1 MYC INHIBITORS AND USES THEREOF StemSynergy Therapeutics, Inc. (US) 2022-12-21 — — EP disclosed
US-11472798-B2 Compounds MISSION THERAPEUTICS LTD (GB) 2022-10-18 — — US disclosed
WO-2021163192-A1 MYC INHIBITORS AND USES THEREOF STEMSYNERGY THERAPEUTICS, INC. (US) 2021-08-19 — — WO disclosed
US-20090264444-A1 Organic compounds XENON PHARMACEUTICALS INC. (CA) 2009-10-22 — — US disclosed
WO-2009012482-A2 5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS H.LUNDBECK A/S (DK) 2009-01-22 — — WO disclosed
US-20080306067-A1 Modulators of Chemokine Receptor Activity WEIGAND KLAUS 2008-12-11 — — US disclosed
EP-1943235-A1 ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Novartis AG (CH) 2008-07-16 — — EP disclosed
US-20080051436-A1 Use of Acylaminothiazole Derivatives as Therapeutic Agents SANOFI-AVENTIS (FR) 2008-02-28 — — US disclosed
US-7291636-B2 Acylaminothiazole derivatives, preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2007-11-06 — — US disclosed
WO-2007048771-A1 ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY NOVARTIS AG (CH) 2007-05-03 — — WO disclosed
US-20050182104-A1 Acylaminothiazole derivatives, preparation and therapeutic use thereof SANOFI-SYNTHELABO (FR) 2005-08-18 — — US disclosed
CN-1057091-C Novelc arbapenem derivatives MEIJI SEIKA CO (JP) 2000-10-04 — — CN disclosed
CN-1148390-A Novelc arbapenem derivatives MEIJI SEIKA CO (JP) 1997-04-23 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306067-A1 Modulators of Chemokine Receptor Activity CCR3, CCR1, CCR4 ALDH1A1 906/4885HPGD 388/4885TSHR 1110/4885
US-20230150956-A1 MYC INHIBITORS AND USES THEREOF MYC, AURKA, AURKC ALDH1A1 4332/4885HPGD 4436/4885TSHR 4277/4885
US-20080051436-A1 Use of Acylaminothiazole Derivatives as Therapeutic Agents BACE1, BACE2, ATG4A ALDH1A1 1460/4885HPGD 2538/4885TSHR 3334/4885
US-20050182104-A1 Acylaminothiazole derivatives, preparation and therapeutic use thereof BACE1, APP, BACE2 ALDH1A1 1639/4885HPGD 2917/4885TSHR 3416/4885
US-11472798-B2 Compounds UCHL1, UCHL3, UCHL5 ALDH1A1 300/4885HPGD 3620/4885TSHR 3585/4885
US-11993595-B2 Compounds UCHL1, UCHL3, UCHL5 ALDH1A1 300/4885HPGD 3620/4885TSHR 3585/4885
US-20090264444-A1 Organic compounds SCD, SCD5, FADS2 ALDH1A1 451/4885HPGD 344/4885TSHR 4191/4885
US-20230052191-A1 NOVEL COMPOUNDS UCHL1, UCHL3, UCHL5 ALDH1A1 285/4885HPGD 3672/4885TSHR 3406/4885
US-12545654-B2 MYC inhibitors and uses thereof MYC, MYCBP, NR2E1 ALDH1A1 4317/4885HPGD 4763/4885TSHR 817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.